SUMO2/3 CHIP-Seq in HL-60 cells treated or not with cytarabine or daunorubicine

SUMOylation, a post-translational modification of the ubiquitin family plays key roles in Acute Myeloid Leukemias response to therapies, in particular through the regulation of gene expression. We have investigated here how daunorubicine (DNR) and cytarabine (Ara-C), the two main drugs used for Acute Myeloid Leukemia treatment, affect the distribution of SUMO on chromatin in the HL-60 cell lines. We found that DNR but not Ara-C leads to a massive decrease in the presence of SUMOylated proteins on the chromatin, in particular at promoters and enhancers, where they are enriched. ChIP-Seq with SUMO2/3 antibodies were performed in pooled triplicate in HL-60 cells treated or not for 2 hours with DNR or AraC.